Baltimore Business Journal
June 12, 2015
Sharon Gerecht, an engineering professor at Johns Hopkins Whiting School of Engineering, has spent years researching tissue repair and regeneration. Repairing tissue and skin usually requires live cells — a treatment that can be costly — but Gerecht’s work has focused on how to make that happen with synthetic materials.
Baltimore startup Gemstone Biotherapeutics is counting on Gerecht’s findings to make a dent in the $15 billion wound care market.
The company, founded on Gerecht’s research, is developing a synthetic version of tissue scaffolding, a thin layer of cells that is applied to a wound to encourage tissue and skin to regrow. Gemstone recently raised $1.6 million to put toward bringing its product from a preclinical stage to the commercial market.
Founding investor Gamma 3 LLC led the seed funding round, which brings Gemstone’s total seed funding to $2.45 million.